ai3Bio Targets Autoimmune Disease at the Cellular Root

ai3Bio is a Watertown, Massachusetts biotechnology company developing a new way to attack autoimmune disease: remove the pathogenic immune cells driving the problem instead of repeatedly suppressing the inflammatory signals they produce. The company publicly launched in September 2026 with $48 million in Series A funding and two preclinical platforms, STARx and T Deplete. ai3Bio is led by Steven Altschuler, MD, CEO; Jonathan Kagan, PhD, scientific co-founder and distinguished scientist; Michael Lyman, PhD, CTO; and Nick Seaver, chief financial and business officer.

Why ai3Bio matters now is straightforward. Autoimmune drug development has produced important medicines, but chronic immune suppression can leave patients rotating through therapies while the disease-driving cell population remains in place. ai3Bio is betting that a selective immune reset can change that equation. The bet is ambitious. It is also still preclinical, which means the company's next data will matter far more than its launch vocabulary.

About ai3Bio

ai3Bio's name points to the three disciplines behind the company: advanced immunology, autoimmunity, and artificial intelligence. Its scientific thesis centers on pathogenic Th17 cells and related T-cell populations that express CD161, a surface marker the company says appeared across diseased tissue analyzed by its AI discovery platform.

That creates a sharper target than “inflammation,” a word broad enough to cover half the pharmacy aisle and several decades of drug-development disappointment. ai3Bio wants to identify the cells producing harmful inflammatory signals, reach them inside the body, and selectively eliminate them while preserving the rest of the immune system.

The company launched with a $48 million Series A led by founding investors UPMC Enterprises and Ziff Capital Partners. Cockrell Interests and Tanis Ventures also participated. ai3Bio has not disclosed a valuation, prior financing under its current name, or investor allocations.

How STARx and T Deplete work

ai3Bio is advancing two complementary approaches against the same underlying cell population. STARx uses an antibody-guided lipid nanoparticle to deliver engineered cGAS mRNA into targeted CD161-positive T cells. The payload is designed to activate the STING pathway and trigger apoptosis, effectively giving the selected cell a carefully addressed self-destruct message.

T Deplete uses a targeted antibody intended to recruit the body's own immune machinery through antibody-dependent cellular cytotoxicity. The platform is designed to remove the same disease-driving cells through a different biological route.

The two-platform strategy matters because drug development rarely rewards a single elegant mechanism merely for being elegant. Multiple modalities give ai3Bio more than one path to test target biology, delivery, selectivity, safety, and indication fit. They also create more ways for the evidence to disagree with the thesis, which is exactly what serious preclinical work is supposed to uncover.

The evidence is promising and early

ai3Bio reports that its lipid-nanoparticle technology removed disease-causing Th17 cells from patient-blood samples. The company also reports that its antibody platform produced efficacy in a non-human-primate autoimmune model, with IND-enabling safety work underway.

Those results support continued development, not a clinical conclusion. The company has not disclosed human safety or efficacy data, a lead indication, trial design, dose, manufacturing partner, or specific regulatory filing date. Its stated goal is to reach an initial patient trial in 2027.

That distinction matters in autoimmune therapeutics. Selectivity is the entire game. A treatment designed to remove pathogenic immune cells must show that it can reach the intended population, spare enough healthy function, control dose and persistence, and produce a meaningful benefit in people. The mechanism can be precise on a slide and messy in a living immune system.

Leadership built around immunology and company formation

Steven Altschuler leads ai3Bio after serving in senior operating and governance roles across health care and biotechnology. Jonathan Kagan brings the scientific center of gravity. In addition to his ai3Bio role, Kagan is the Marian R. Neutra Professor of Pediatrics at Harvard Medical School and directs basic research in gastroenterology at Boston Children's Hospital.

Michael Lyman leads technology, and Nick Seaver leads finance and business development. Fabian Tenenbaum, executive vice president at UPMC Enterprises, chairs the board. The scientific advisory board includes John Maraganore, Vijay Kuchroo, Ruslan Medzhitov, Alexander Rudensky, Arlene Sharpe, Dario Vignali, and Greg Delgoffe, according to the company.

That roster gives ai3Bio strong scientific and company-building credibility. It does not remove development risk. Its real value is in helping the company ask harder questions earlier, before capital and calendar time turn a weak assumption into a very expensive tradition.

Why the market should pay attention

A U.S. prevalence study summarized by Mayo Clinic estimated that roughly 15 million Americans were diagnosed with at least one of 105 autoimmune diseases during the study period. The category is enormous, fragmented, and full of therapies that can manage disease without reliably creating durable remission.

ai3Bio reflects a broader shift in biotechnology from blocking individual inflammatory outputs toward redesigning or depleting specific immune-cell populations. It also represents a more disciplined use of AI than the industry slogan usually suggests. Here, AI is not the medicine. It is part of the discovery system used to identify a targetable biological pattern. The therapeutics still have to survive pharmacology, toxicology, manufacturing, regulation, and clinical reality.

For founders and investors, the company is a test of whether computational tissue analysis can produce a target with enough biological leverage to support multiple therapeutic modalities. For operators, it is a reminder that platform value only appears when a company converts shared science into repeatable development decisions.

ai3Bio has assembled capital, experienced leadership, and a coherent mechanistic thesis. The next chapter will be written by selectivity data, regulatory progress, and eventually patients. If STARx or T Deplete can remove the right cells without creating a different immune problem, ai3Bio may help move autoimmune care from chronic suppression toward a genuine reset. Until then, the opportunity is credible, the ambition is large, and the evidence bar is exactly where it should be: high.